A new study using lab-engineered microtumors allowed doctors to better predict if a cancer drug treatment will work in a patient. » Read More
By: Dan Mangan
Shkreli will be sentenced March 9 on for three federal crimes related to hedge funds he ran, and a drug company he founded. » Read More
Novo Nordisk presented the first successful data from a large final-stage study of a pill it hopes will transform the diabetes market. » Read More
By: Angelica LaVito
The products could spark a price war and put pressure on other store-brand profit margins. » Read More
Aimmune Therapeutics' peanut allergy drug met the main goal of a late-stage study, sending shares sharply higher.
J.P. Morgan alerted clients to two biotech companies that it believes could outperform peers in the next year.
Experts look at the mental state of mass shooters like Nikolas Cruz who murdered 17 people at a Parkland, Florida, high school Wednesday.
Flu shots are 36 percent effective overall so far this season, according to preliminary data from the CDC.
Peter Diamandis, Celularity co-founder and vice chairman, and Bob Hariri, Celularity co-founder, chairman and CEO, talk about the future of cellular medicine as scientist develop ways to reengineer living cells.
CNBC's Meg Tirrell looks at Bristol-Myers buying the drug testing rights for a cancer drug from Nektar Therapeutics.
The Food and Drug Administration has approved Glooko's Mobile Insulin Dosing System.
Former Celgene Chairman and CEO Bob Hugin says the U.S. is failing to adequately address the increasing inequality of health care.
The 76-year-old Stefano Pessina started with a local family drug distribution business.
Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis patients.
The Wall Street Journal reports that Walgreens has had talks with AmerisourceBergen about buying the rest of the company it does not already own.
Former Celgene executive Bob Hugin is entering New Jersey's Republican Senate primary in an attempt to oust incumbent Democrat Bob Menendez.
CNBC's Meg Tirrell reports headlines from the big health care and pharma stories of the day.
Amgen, the world's largest biotech company, has said it is "looking hard" for deals to deploy its $27bn cash pile, according to the Financial Times.
OxyContin maker Purdue Pharma LP said on Saturday that it has cut its sales force in half and will stop promoting opioids to physicians.
Jim Cramer finds bull and bear cases in the Dow Jones industrial average's biggest losers from the week's sell-off.
Get the best of CNBC in your inbox